Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$15.19
$8.13
$19.08
$24.33M0.4123,064 shs237,144 shs
Endo International plc stock logo
ENDP
Endo International
$0.45
$0.28
$7.07
$141K1.1528.19 million shs9,967 shs
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$1.10
+4.8%
$0.98
$0.81
$1.82
$54.55M1.49196,252 shs439,255 shs
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
$17.59
$17.67
$9.93
$32.94
$818.60M1.454,965 shsN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
$12.89
+3.9%
$12.21
$8.32
$17.70
$896.85M1.17587,713 shs288,511 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00%0.00%0.00%+4.31%+68.57%
Endo International plc stock logo
ENDP
Endo International
0.00%0.00%0.00%0.00%0.00%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-0.94%-9.48%+21.25%+5.00%-33.54%
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
0.00%0.00%0.00%0.00%0.00%
Zymeworks Inc. stock logo
ZYME
Zymeworks
-1.12%-3.20%+6.34%+4.11%+44.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.3168 of 5 stars
0.00.00.04.20.60.80.0
Endo International plc stock logo
ENDP
Endo International
0.2482 of 5 stars
0.00.00.03.50.01.70.0
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
2.8525 of 5 stars
3.53.00.00.02.71.70.6
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
N/AN/AN/AN/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.958 of 5 stars
3.51.00.00.01.53.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00
N/AN/AN/A
Endo International plc stock logo
ENDP
Endo International
0.00
N/AN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
3.00
Buy$5.50400.00% Upside
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
0.00
N/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.90
Moderate Buy$21.0062.92% Upside

Current Analyst Ratings Breakdown

Latest CARA, ZYME, ENDP, ZEAL, and PMVP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$7.14M0.00N/AN/A$12.58 per share0.00
Endo International plc stock logo
ENDP
Endo International
$2.99B0.00N/A0.06($13.60) per share0.00
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/A$3.40 per shareN/A
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
$46.54M17.59N/AN/A$3.38 per share5.20
Zymeworks Inc. stock logo
ZYME
Zymeworks
$93.38M9.60N/AN/A$6.63 per share1.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/A
Endo International plc stock logo
ENDP
Endo International
-$613.24M-$11.07N/A0.00N/A-93.31%-34.25%6.72%N/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$58.71M-$1.18N/AN/AN/AN/A-32.54%-29.59%8/6/2025 (Estimated)
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
-$161.99M-$4.09N/AN/AN/A-565.44%-111.04%-56.54%N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%7/30/2025 (Estimated)

Latest CARA, ZYME, ENDP, ZEAL, and PMVP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$0.37-$0.34+$0.03-$0.34N/AN/A
5/8/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/AN/AN/AN/AN/A
Endo International plc stock logo
ENDP
Endo International
N/AN/AN/AN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/AN/A
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/A
4.77
4.71
Endo International plc stock logo
ENDP
Endo International
N/A
1.86
1.62
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/A
16.75
16.75
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
0.93
4.79
4.78
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
44.66%
Endo International plc stock logo
ENDP
Endo International
80.39%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
90.20%
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
1.73%
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
804.57 million4.43 millionOptionable
Endo International plc stock logo
ENDP
Endo International
3,103235.14 million232.32 millionNo Data
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
5051.95 million48.02 millionOptionable
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
35546.54 million45.51 millionNot Optionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
46069.58 million67.56 millionOptionable

Recent News About These Companies

Zymeworks’ zanidatamab approved in China

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cara Therapeutics stock logo

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Endo International stock logo

Endo International NASDAQ:ENDP

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

PMV Pharmaceuticals stock logo

PMV Pharmaceuticals NASDAQ:PMVP

$1.10 +0.05 (+4.76%)
Closing price 04:00 PM Eastern
Extended Trading
$1.12 +0.02 (+1.73%)
As of 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Zealand Pharma A/S stock logo

Zealand Pharma A/S NASDAQ:ZEAL

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Zymeworks stock logo

Zymeworks NYSE:ZYME

$12.89 +0.48 (+3.87%)
Closing price 04:00 PM Eastern
Extended Trading
$12.76 -0.14 (-1.05%)
As of 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.